LEO Pharma Presents 3.5 Year Interim Safety & Efficacy Data in P-III (ECZTEND) Trial of Adbry (tralokinumab-ldrm) for Atopic Dermatitis at AAD 2022

Published: Mar 25, 2022 | Tags: LEO Pharma, P-III, ECZTEND Trial, Adbry, tralokinumab-ldrm, Atopic Dermatitis, AAD 2022

Janssen’s Cabenuva (rilpivirine and cabotegravir) Receives the US FDA’s Label Update Approval for the Treatment of HIV

Published: Mar 25, 2022 | Tags: Janssen, Cabenuva, rilpivirine, cabotegravir, US, FDA, Label Update, Approval, HIV

Medtronic Reports the First Patient Implant in (TITAN 2) Study of Implantable Tibial Neuromodulation Device for Overactive Bladder

Published: Mar 25, 2022 | Tags: Medtronic, TITAN 2 Study, Implantable Tibial Neuromodulation Device, Overactive Bladder

Jazz Reports the First Patient Enrollment in the P-II (EMERGE-201) Basket Trial of Zepzelca (lurbinectedin) for Advanced or Metastatic Solid Tumors

Published: Mar 25, 2022 | Tags: Jazz, P-II, EMERGE-201, Basket Trial, Zepzelca, lurbinectedin, Solid Tumors

AstraZeneca's Evusheld Receives CHMP's Recommendation for Approval in the EU for the Pre-Exposure Prophylaxis of COVID-19 in the EU

Published: Mar 25, 2022 | Tags: AstraZeneca, Evusheld, Approval, EU, Pre-Exposure Prophylaxis, COVID-19

Halozyme Signs a Collaboration and License Agreement with Chugai for Enhanze Drug-Delivery Technology

Published: Mar 25, 2022 | Tags: Halozyme, Chugai, Enhanze, Drug-Delivery Technology

Pfizer’s Respiratory Syncytial Virus Vaccine (PF-06928316 or RSVpreF) Receives the US FDA’s Breakthrough Therapy Designation for RSV

Published: Mar 24, 2022 | Tags: Pfizer, Respiratory Syncytial Virus Vaccine, PF-06928316, RSVpreF, US, FDA, Breakthrough Therapy Designation, RSV

PharmaTher Reports Results of Ketamine in a Clinical Study for the Treatment of Parkinson’s Disease

Published: Mar 24, 2022 | Tags: PharmaTher, Ketamine, Parkinson’s Disease

argenx Reports Results of Vyvgart (efgartigimod alfa-fcab) in P-III (ADAPT-SC) Study for the Treatment of Generalized Myasthenia Gravis

Published: Mar 24, 2022 | Tags: argenx, Vyvgart, efgartigimod alfa-fcab, P-III, ADAPT-SC Study, Generalized Myasthenia Gravis

Silence Therapeutics and Mallinckrodt Submit Clinical Trial Application for SLN501 to Treat Complement-Mediated Diseases

Published: Mar 24, 2022 | Tags: Silence, Mallinckrodt, Clinical Trial Application, SLN501, Complement-Mediated Diseases

Moderna Reports Interim Results of COVID-19 Vaccine (mRNA-1273) in P-II/III (KidCOVE) Study for Children Aged 6 Months to Under 6 Years

Published: Mar 24, 2022 | Tags: Moderna, COVID-19 Vaccine, mRNA-1273, P-II/III, KidCOVE Study

Pfizer Reports Results of Etrasimod in P-III (ELEVATE 12) Trial for the Treatment of Ulcerative Colitis

Published: Mar 24, 2022 | Tags: Pfizer, Etrasimod, P-III, ELEVATE 12 Trial, Ulcerative Colitis

GSK Entered into a R&D Collaboration with LifeMine to Discover Novel Therapies for Multiple Disease

Published: Mar 23, 2022 | Tags: GSK, LifeMine, Avatar-Rx Platform, Multiple Disease

Palisade Bio Receives the US FDA’s Study May Proceed Letter for P-III Clinical Trial of LB1148 to Improved Bowel Function After Abdominal Surgery

Published: Mar 23, 2022 | Tags: Palisade Bio, US, FDA, P-III, Clinical Trial, LB1148, Bowel Function, Abdominal Surgery

Novavax and Serum Institute of India’s NVX-CoV2373 Receives the DCGI's EUA for the Treatment of COVID-19 in Adolescents Aged ≥12 to <18 Years in India

Published: Mar 23, 2022 | Tags: Novavax, Serum Institute of India, NVX-CoV2373, DCGI, EUA, COVID-19, India

Aligos Discontinues ALG-020572 in the (ALG-020572-401) Study for the Treatment of Chronic Hepatitis B

Published: Mar 23, 2022 | Tags: Aligos, ALG-020572, ALG-020572-401 Study, Chronic Hepatitis B

BioMarin’s Vimizin (elosulfase alfa) Receives NICE Recommendation for the Treatment of Mucopolysaccharidosis Type 4A

Published: Mar 23, 2022 | Tags: BioMarin, Vimizin, elosulfase alfa, NICE, Recommendation, Mucopolysaccharidosis Type 4A

ObsEva Reports Efficacy Results of Linzagolix in the P-III (EDELWEISS 3) Trial for the Treatment of Endometriosis-Associated Pain

Published: Mar 23, 2022 | Tags: ObsEva, Linzagolix, P-III, EDELWEISS 3 Trial, Endometriosis-Associated Pain

Plus Therapeutics Reports First Patient Dosing in P-I/IIa (ReSPECT-LM) Dose Escalation Trial of 186RNL for Leptomeningeal Metastases

Published: Mar 22, 2022 | Tags: Plus Therapeutics P-I/IIa, ReSPECT-LM, Dose Escalation Trial, 186RNL, Leptomeningeal Metastases

GeNeuro Reports Results of Temelimab + Rituximab in P-II (ProTEct-MS) trial for the Treatment of Multiple Sclerosis

Published: Mar 22, 2022 | Tags: GeNeuro, Temelimab, Rituximab, P-II, ProTEct-MS Trial, Multiple Sclerosis

Ascentage Pharma's Alrizomadlin (APG-115) Receives the US FDA’s Rare Pediatric Disease Designation for the Treatment of Neuroblastoma

Published: Mar 22, 2022 | Tags: Ascentage Pharma, Alrizomadlin, APG-115, US, FDA, Rare Pediatric Disease Designation, Neuroblastoma

uniQure Reports Completion of Patient Enrollment in the First Two Cohorts of P-I/II Trial for AMT-130 to Treat Huntington’s Disease

Published: Mar 22, 2022 | Tags: uniQure, P-I/II Trial, AMT-130, Huntington’s Disease

Tonix Reports Results of TNX-102 SL in P-III (RALLY) Study for the Treatment of Fibromyalgia

Published: Mar 22, 2022 | Tags: Tonix, TNX-102 SL, P-III, RALLY Study, Fibromyalgia

Merck’s Keytruda (pembrolizumab) Receives the US FDA’s Approval for the Treatment of MSI‑H/dMMR Advanced Endometrial Carcinoma

Published: Mar 22, 2022 | Tags: Merck, Keytruda, pembrolizumab, US, FDA, Approval, MSI‑H/dMMR, Endometrial Carcinoma

Nuance Pharma Signs a License and Supply Agreement with Bavarian Nordic to Develop and Commercialize of Respiratory Syncytial Virus Vaccine

Published: Mar 21, 2022 | Tags: Nuance Pharma, Bavarian Nordic, Respiratory Syncytial Virus Vaccine,

Scilex Reports Efficacy and Safety Results of Semdexa (SP-102) P-III (C.L.E.A.R.) Program for Sciatica Pain Management

Published: Mar 21, 2022 | Tags: Scilex, Semdexa, SP-102, P-III, C.L.E.A.R. Program, Sciatica Pain Management

BMS Collaborated with Volastra to Develop and Commercialize Novel Therapies for Cancer

Published: Mar 21, 2022 | Tags: BMS, Volastra, Therapies, Cancer, CINtech platform

Marinus’ Ztalmy (ganaxolone) Receives the US FDA’s Approval for the Treatment of CDKL5 Deficiency Disorder

Published: Mar 21, 2022 | Tags: Marinus, Ztalmy, ganaxolone, US, FDA, Approval, CDKL5 Deficiency Disorder

Merck Presents Results of Keytruda (pembrolizumab) in P-III (KEYNOTE-09) Trial for Stage IB-IIIA NSCLC Regardless of PD-L1 Expression at ESMO 2022

Published: Mar 21, 2022 | Tags: Merck, Keytruda, pembrolizumab, P-III, KEYNOTE-09 Trial, Stage IB-IIIA, NSCLC, PD-L1 Expression

BMS’ Opdualag (nivolumab and relatlimab-rmbw) Receives the US FDA’s Approval for the Treatment of Unresectable or Metastatic Melanoma

Published: Mar 21, 2022 | Tags: BMS, Opdualag, nivolumab, relatlimab-rmbw, US, FDA, Approval, Metastatic, Melanoma

Related Post: PharmaShots Weekly Snapshots (March 07-11, 2022)